Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | KIF5B | P33176 | 2/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569119 | 0.88 | TP53 (0.50) | TP53POLBRETKIF5BKDR | |
| SCHEMBL5568231 | 0.79 | EGFR (0.64) | TP53RAF1MEN1NPC1KMT2A | |
| SCHEMBL5568069 | 0.79 | JAK2 (0.56) | TP53MEN1NPC1POLBKMT2A | |
| SCHEMBL14511293 | 0.76 | NCOA1 (0.61) | BRD4RAF1BRAFMEN1POLB | |
| SCHEMBL5564578 | 0.73 | MAPT (0.55) | TP53NPC1EGFRFADS1LCK | |
| SCHEMBL5565322 | 0.73 | AURKA (0.52) | TP53NPC1KDREGFRFADS1 | |
| SCHEMBL4787438 | 0.73 | TNNI3K (0.62) | BRD4BRAFEGFR | |
| SCHEMBL18292470 | 0.72 | MEN1 (0.65) | BRD4RAF1BRAFMEN1NPC1 | |
| SCHEMBL7118883 | 0.72 | SRC (0.74) | TP53RAF1MEN1KMT2ARET | |
| SCHEMBL5568040 | 0.71 | EGFR (0.60) | MEN1NPC1POLBKMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | BRD4 30/4885TP53 135/4885RAF1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.